XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements GlobeNewswire November 12, 2025 Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed XOMA Royalty's acquisitions of Turnstone Biologics and HilleVax; • announced […]

Abeona Therapeutics(R) Reports Third Quarter 2025 Financial Results and Corporate Updates

Abeona Therapeutics(R) Reports Third Quarter 2025 Financial Results and Corporate Updates GlobeNewswire November 12, 2025 – First anticipated ZEVASKYN(R) patient treatment shifted to 4Q 2025 following implementation of optimized release assay – – Strong and growing patient demand and treatment site network, along with broad market access provide foundation for sustainable commercial success – –

Terra Clean Closes the Acquisition of the Past Producing Uranium Claims in San Rafael Swell, Utah, United States

Terra Clean Closes the Acquisition of the Past Producing Uranium Claims in San Rafael Swell, Utah, United States GlobeNewswire November 12, 2025 Vancouver B.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — TERRA CLEAN ENERGY CORP. (“Terra” or the “Company“) (CSE: TCEC, OTCQB: TCEFF, FSE: C9O0), is pleased to announce that, further to its press release dated

Lantronix CEO to Participate in Craig-Hallum, ROTH and Headgate Partners Investor Conferences

Lantronix CEO to Participate in Craig-Hallum, ROTH and Headgate Partners Investor Conferences GlobeNewswire November 12, 2025 IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions powering Edge AI applications, today announced that its CEO Saleel Awsare will participate in three upcoming investor conferences:

Forterra Closes $238 Million Series C, Cementing Leadership in Autonomy and Interoperable Systems

Forterra Closes $238 Million Series C, Cementing Leadership in Autonomy and Interoperable Systems GlobeNewswire November 12, 2025 Washington, D.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Forterra, the company redefining autonomy and mission system interoperability for defense and logistics, today announced it closed a $238 million Series C in equity and debt. The round was led

Brixton Metals Drills 112 g/t Gold Over 0.50m with Visible Gold Within 23.50m of 3.33 g/t Gold at Trapper Target

Brixton Metals Drills 112 g/t Gold Over 0.50m with Visible Gold Within 23.50m of 3.33 g/t Gold at Trapper Target And 18.50m of 3.39 g/t Gold, Including 3.00m of 15.69 g/t Gold GlobeNewswire November 12, 2025 VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or

Habit Celebrates “Good Habits Day” with Free Double Charburgers to Support No Kid Hungry

Habit Celebrates “Good Habits Day” with Free Double Charburgers to Support No Kid Hungry Doing good never tasted so good. Join Habit on Nov 15 for Good Habits Day. GlobeNewswire November 12, 2025 IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Habit is celebrating its 56th birthday the best way it knows how: by giving

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results GlobeNewswire November 12, 2025 Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEXâ‚₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards Commercial Manufacturing Readiness

BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates GlobeNewswire November 12, 2025 Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S.

Verde Announces Q3 2025 Earnings Results

Verde Announces Q3 2025 Earnings Results GlobeNewswire November 12, 2025 SINGAPORE, Nov. 12, 2025 (GLOBE NEWSWIRE) — Verde AgriTech Ltd (TSX: NPK | OTCQX: VNPKF) (“Verde” or the “Company“) announces its operating and financial results for the period ended September 30, 2025 (“Q3 2025“). All figures are in Canadian dollars, unless stated otherwise. Average exchange

Scroll to Top